Results 121 to 130 of about 5,389 (186)

Decellularized Dermis ECM-Based Melanoma-on-a-Chip Model with Integrated Lymphatic and Vascular Networks for High-Throughput Drug Testing. [PDF]

ACS Appl Bio Mater
Vázquez-Aristizabal P, Arriola-Alvarez I, Henriksen-Lacey M, Alonso-Martin S, van den Broek L, Liz-Marzán LM, Izeta A.   +6 more
europepmc   +1 more source

Implementation of a lifestyle‐based clinical pathway in daily clinical practice in men undergoing androgen deprivation therapy for prostate cancer [PDF]

, 2019
Bruggeman, Anniek, Bultijnck, Renée, De Muynck, Martine, Decaestecker, Karel, Deforche, Benedicte, Fonteyne, Valerie, Lumen, Nicolaas, Mortier, Stefanie, Ost, Piet, Raes, Anneleen, Rammant, Elke, Van Ruymbeke, Barbara   +11 more
core   +1 more source

Eruptive nevi in the setting of encorafenib: A case report and literature review

JAAD Case Reports
Marisa Lenga, BS, Samantha Venkatesh, MD, Jennifer Nam Choi, MD   +2 more
doaj   +1 more source

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial. [PDF]

Nat Commun
Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A.   +28 more
europepmc   +1 more source

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF^V600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison. [PDF]

ESMO Open
Planchard D, Mazières J, Grouin JM, Le Reun C, Luttenauer H, Boussahoua M, Macabeo B.   +6 more
europepmc   +1 more source

COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma. [PDF]

Future Oncol
Schadendorf D.
europepmc   +1 more source

Ophthalmic Toxicities in BEACON Triplet Therapy for BRAF V600E-Mutant Colorectal Cancer: A Case Series. [PDF]

J Anus Rectum Colon
Nakamura H, Suzumura K, Oiwa K, Tsuchiya T, Nishimae K, Tanaka M, Terasaki M, Okamoto Y.   +7 more
europepmc   +1 more source

Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series. [PDF]

Melanoma Manag
Nassief G, Morecroft R, Phillipps J, Chen D, Ansstas G.   +4 more
europepmc   +1 more source

Surrogate to predict overall survival in patients with <i>BRAF</i> V600E-mutant colorectal cancer treated with BRAF inhibitor combinations. [PDF]

ESMO Gastrointest Oncol
Ros J, Navarro V, Villacampa G, Baraibar I, Salvà F, Rodriguez M, Vaghi C, Garcia A, Alcaraz A, Tabernero J, Élez E, Dienstmann R.   +11 more
europepmc   +1 more source

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. [PDF]

J Clin Oncol
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.   +20 more
europepmc   +1 more source